Werewolf Therapeutics is a clinical-stage biotech aligning its entire pipeline with its PREDATOR™ platform, engineering pro-drugs that activate selectively in tumor environments to enhance efficacy and safety in cancer immunotherapies. Its lead candidates—WTX-124 (IL-2) and WTX-330 (IL-12)—are in early clinical trials, while its INDUCER TCE program is preparing for clinical entry. Despite compelling scientific advances and an FDA Fast Track designation, the stock trades below cash on hand, pricing in nearly total failure due to the company’s precarious financial state. The investment case rests on upcoming clinical data as a pivotal binary catalyst: success could vindicate the platform, attract partnerships, and enable transformative financing, while failure would likely lead to liquidation.